Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
-2.34 |
-2.35 |
-0.01 |
-0.43% |
2024-02-22 |
2023-12 |
-0.7 |
-0.7 |
N/A |
N/A |
2024-02-22 |
2023-12 |
-0.7 |
N/A |
N/A |
N/A |
2023-11-07 |
2023-09 |
-0.76 |
-0.76 |
N/A |
N/A |
2023-11-07 |
2023-09 |
-0.76 |
N/A |
N/A |
N/A |
2023-08-01 |
2023-06 |
-0.8 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-09 |
Morgan Stanley |
Upgrade |
Equal-Weight |
Equal-Weight |
2023-08-01 |
Morgan Stanley |
Upgrade |
Equal-Weight |
Equal-Weight |
2023-08-01 |
B of A Securities |
Upgrade |
Neutral |
Buy |
2023-08-01 |
Needham |
Upgrade |
Buy |
Buy |
2023-06-19 |
Needham |
Upgrade |
Buy |
Buy |
2023-04-17 |
Needham |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-03-19 |
CHIEN JENNIFER |
Officer |
6.85K |
Sale |
2024-03-18 |
CRAMER PAMELA J. |
Officer |
30.01K |
Sale |
2021-03-14 |
FOLEY TODD |
Director |
0.00 |
Sale |
2024-04-01 |
GERMAN CHRISTOPHER PAUL |
Officer |
795.00 |
Sale |
2024-04-11 |
MAZABRAUD YANN |
Officer |
34.87K |
Conversion of Exercise of derivative security |
2024-03-18 |
MEEKER DAVID P |
Chief Executive Officer |
174.61K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Primecap Management Company |
8.30M |
136.86M |
14.59% |
2023-06-29 |
Baker Brothers Advisors, LLC |
6.50M |
107.16M |
11.42% |
2023-06-29 |
Blackrock Inc. |
6.27M |
103.31M |
11.01% |
2023-06-29 |
RA Capital Management, L.P. |
5.68M |
93.60M |
9.98% |
2023-06-29 |
Goldman Sachs Group Inc |
5.19M |
85.52M |
9.11% |
2023-06-29 |
Federated Hermes, Inc. |
3.89M |
64.17M |
6.84% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-07-30 |
Primecap Odyssey Aggressive Growth Fund |
5.39M |
96.23M |
9.48% |
2023-07-30 |
Primecap Odyssey Growth Fund |
2.55M |
45.50M |
4.48% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
2.19M |
56.85M |
3.84% |
2023-07-30 |
Federated Hermes Kaufmann Fund |
2.07M |
36.93M |
3.64% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.74M |
28.72M |
3.06% |
2023-07-30 |
Federated Hermes Kaufmann Small Cap Fund |
1.51M |
26.98M |
2.66% |